The COVID-19 pandemic has presented challenges and opportunities for substance disorder treatment. IRETA and Vital Strategies are studying effects of OTP rule changes.
Evidence-Based and Best Practices
The National Institutes of Health (NIH) released a study that shows a combination of two medications, injectable naltrexone and oral bupropion, is safe and effective in treating methamphetamine use disorder.
I don’t believe that we can truly understand what those teachers lecturing about clinician burnout means until we’re “in the trenches” of this field. Let’s talk about compassion fatigue.
IRETA has hosted medical students in Pittsburgh for the Scaife Medical Student Fellowship in Substance Use Disorders. The fellowship offers medical students, typically between their first and second years of medical school, an intensive learning experience about substance use, addiction, and addiction treatment.
IRETA was fortunate to be chosen to work with Foundations Medical Services, a methadone maintenance program in Butler, PA managed by Pyramid Healthcare, Inc.
Every generation struggles with their own set of public health issues. Our generation is faced with the opioid epidemic–which has been brewing for over 20 years. Let’s dispelling misconceptions about liability risk associated with dispensing naloxone.
Addressing the public health consequences of alcohol use disorder means doing more work in primary care.
Peer-reviewed evaluation results indicate that students feel more responsible and motivated to help people with substance use disorders
Here are three strategies that the federal government should consider to ensure that naloxone is truly accessible.
IRETA works with courts to ensure that individuals on community supervision are receiving appropriate, high-quality care.